Four Tower Bridge
Suite 200 200 Barr Harbor Drive
West Conshohocken, PA 19428
United States
267 824 2827
https://www.madrigalpharma.com
Settore/i:
Settore:
Impiegati a tempo pieno: 376
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Rebecca A. Taub M.D. | Founder, Chief Medical Officer, President of Research & Development and Director | 939,83k | N/D | 1952 |
Mr. Brian J. Lynch J.D. | Senior VP & General Counsel | 763,75k | 1,27M | 1962 |
Mr. Alex G. Howarth | Executive Officer | 757,26k | N/D | 1969 |
Mr. William J. Sibold | CEO, President & Director | N/D | N/D | 1966 |
Ms. Mardi C. Dier | CFO, Principal Financial Officer, Principal Accounting Officer & Senior VP | N/D | N/D | 1964 |
Mr. Ronald Filippo | Chief Information Officer | N/D | N/D | N/D |
Ms. Tina E. Ventura | Chief Investor Relations Officer | N/D | N/D | N/D |
Dr. Kianoush Motesharei Ph.d. | Senior Vice President of Business & Corporate Development | N/D | N/D | 1970 |
Mr. Clint Wallace | Chief Human Resources Officer | N/D | N/D | N/D |
Mr. Edward Chiang | Senior Vice President of Clinical & Technical Operations | N/D | N/D | N/D |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
L'ISS Governance QualityScore di Madrigal Pharmaceuticals, Inc. al 1 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 9; diritti degli azionisti: 8; retribuzione: 7.